Defining the term “strain” is a conscientious issue within the microbiome field. Broadly speaking, a bacterial strain is a sub-group within a species with unique characteristics such as genetic makeup, metabolism, and morphology. But standards […]
“We want to empower patients and researchers in the microbiome field”, Heloise is passionately describing the applications of DNA Genotek’s FDA-authorised sample collection device “OMNIgene•GUT Dx” to me over zoom. In 2022, the device, which stabilises […]
The Dutch government has reserved €200 million from its National Growth Fund for the establishment of the Holomicrobiome Institute and its activities during the first ten years. The reservation was announced by Minister Adriaansens of […]
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks of growth retardation, sepsis and NEC which leads to increased mortality. Hospital stays for these […]
Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, […]
Exeliom Biosciences (formerly Nextbiotix), a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies, announced the completion of its €24 million ($26 million) Series A with a last extension […]
Pendulum Therapeutics, the biotech company pioneering the next frontier of metabolic health through its microbiome-targeted products, announced a strategic partnership with New Zealand dairy nutrition company Fonterra. Fonterra will invest $10 million into the growth-stage […]
Concerto Biosciences announced the launch of a discovery endeavor to develop a new microbial product for the treatment of vulvovaginal candidiasis (VVC), a vaginal yeast infection that adversely affects 75% of women at some point […]
Freya Biosciences, a trans-Atlantic biotech company specializing in women’s health, announces positive topline results from its first Phase 1 clinical study of its lead asset FB101, an investigational vaginal microbial immunotherapeutic. These data allow the […]
A Cleveland Clinic research team recently published an “atlas” of metabolites associated with cardiovascular disease in the European Heart Journal. The novel findings provide key details about the routes and potential branching paths taken by bacteria and […]
The new biotech venture PHIOGEN is a spin-off company from Baylor College of Medicine’s TAILOR Labs, one of the United States only academic phage therapy cores with a decade’s worth of revolutionary research related to bacteriophages, viruses that infect […]